Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Core Event: Colossal Biosciences, a de-extinction startup, is in talks to raise new funding at a $20 billion to $30 billion valuation. The company has generated revenue over the last year and has three revenue streams: conservation technology, spun-out startups, and potential biodiversity credits from reintroducing extinct animals. Colossal co-founder and CEO Ben Lamm plans to spin off its artificial animal womb technology next year, which could have applications for human fertility treatment. Important specifics: The new fundraising effort comes amid a boom in longevity tech, alternative energy, and other deep-tech sectors. Colossal has already raised $200 million at a $10.2 billion valuation last year and has spun out three startups, including Breaking, Form Bio, and Astromech. The company operates out of a 55,000-square-foot headquarters in Dallas. Market implications: If successful, the fundraising effort could indicate growing interest in de-extinction tech and its potential applications in conservation and human health. It may also signal increasing investment in deep-tech sectors such as longevity and alternative energy.
Story 1 of 10